GATA factor mutations in hematologic disease

Blood

Volumn 129, Issue 15, 2017, Pages 2103-2110

  Crispino, John D ^a   Horwitz, Marshall S ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; GATA1 PROTEIN, HUMAN; GATA2 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; BLACKFAN DIAMOND ANEMIA; BONE MARROW DEPRESSION; CLINICAL FEATURE; CONGENITAL DYSERYTHROPOIETIC ANEMIA; GATA2 DEFICIENCY SYNDROME; GENETICS; GERMLINE MUTATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; ANIMAL; METABOLISM; MUTATION;

ANEMIA, DIAMOND-BLACKFAN; ANIMALS; GATA1 TRANSCRIPTION FACTOR; GATA2 TRANSCRIPTION FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HUMANS; MUTATION;

EID: 85018863155     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-687889     Document Type: Review

References (112)

1. Chlon TM, Crispino JD. Combinatorial regulation of tissue specification by GATA and FOG factors. Development. 2012;139(21):3905-3916.
2. Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: Mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res. 2012;40(13):5819-5831.
3. Crispino JD, Weiss MJ. Erythro-megakaryocytic transcription factors associated with hereditary anemia. Blood. 2014;123(20):3080-3088.
4. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152.
5. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101(11): 4298-4300.
6. Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol. 2015;169(2):173-187.
7. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653-2655.
8. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627.
9. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4): 309-315
10. Shiba N, Funato M, Ohki K, et al. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. Br J Haematol. 2014; 164(1):142-145.
11. Zhang SJ, Ma LY, Huang QH, et al. Gain-offunction mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci USA. 2008;105(6):2076-2081.
12. Wang Y, Misumi I, Gu AD, et al. GATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling. Nat Immunol. 2013;14(7):714-722.
13. Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature. 2000;406(6794):419-422.
14. Ping Z, Xia Y, Shen T, et al. A microscopic landscape of the invasive breast cancer genome. Sci Rep. 2016;6:27545.
15. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45(12): 1494-1498.
16. Peterkin T, Gibson A, Loose M, Patient R. The roles of GATA-4, -5 and -6 in vertebrate heart development. Semin Cell Dev Biol. 2005;16(1): 83-94.
17. Ackerman C, Locke AE, Feingold E, et al. An excess of deleterious variants in VEGF-A pathway genes in Down-syndrome-associated atrioventricular septal defects. Am J Hum Genet. 2012;91(4):646-659.
18. Evans T, Reitman M, Felsenfeld G. An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. Proc Natl Acad Sci USA. 1988;85(16):5976-5980.
19. Martin DI, Tsai SF, Orkin SH. Increased gammaglobin expression in a nondeletion HPFH mediated by an erythroid-specific DNA-binding factor. Nature. 1989;338(6214):435-438.
20. Wall L, deBoer E, Grosveld F. The human betaglobin gene 39 enhancer contains multiple binding sites for an erythroid-specific protein. Genes Dev. 1988;2(9):1089-1100.
21. Trainor CD, Omichinski JG, Vandergon TL, Gronenborn AM, Clore GM, Felsenfeld G. A palindromic regulatory site within vertebrate GATA-1 promoters requires both zinc fingers of the GATA-1 DNA-binding domain for high-affinity interaction. Mol Cell Biol. 1996;16(5):2238-2247.
22. Tsang AP, Visvader JE, Turner CA, et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell. 1997;90(1): 109-119.
23. Martin DI, Orkin SH. Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1. Genes Dev. 1990;4(11): 1886-1898.
24. Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA. 1996;93(22):12355-12358.
25. Weiss MJ, Orkin SH. Transcription factor GATA- 1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci USA. 1995;92(21):9623-9627.
26. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood. 1999;94(1):87-96.
27. Gutiérrez L, Tsukamoto S, Suzuki M, et al. Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood. 2008;111(8): 4375-4385.
28. McDevitt MA, Shivdasani RA, Fujiwara Y, Yang H, Orkin SHA. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA. 1997;94(13):6781-6785.
29. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16(13):3965-3973.
30. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(9):2867-2875.
31. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005;106(4):1223-1231.
32. Kuhl C, Atzberger A, Iborra F, Nieswandt B, Porcher C, Vyas P. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol. 2005;25(19): 8592-8606.
33. Migliaccio AR, Rana RA, Sanchez M, et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med. 2003;197(3): 281-296.
34. Yu C, Cantor AB, Yang H, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002; 195(11):1387-1395.
35. Hirasawa R, Shimizu R, Takahashi S, et al. Essential and instructive roles of GATA factors in eosinophil development. J Exp Med. 2002; 195(11):1379-1386.
36. Nei Y, Obata-Ninomiya K, Tsutsui H, et al. GATA-1 regulates the generation and function of basophils. Proc Natl Acad Sci USA. 2013; 110(46):18620-18625.
37. Kozma GT, Martelli F, Verrucci M, et al. Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. Exp Hematol. 2010;38(6):489-503.e1.
38. Tsang AP, Fujiwara Y, Hom DB, Orkin SH. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev. 1998; 12(8):1176-1188.
39. Chang AN, Cantor AB, Fujiwara Y, et al. GATAfactor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci USA. 2002;99(14):9237-9242.
40. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24(3):266-270.
41. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98(9):2681-2688.
42. Freson K, Devriendt K, Matthijs G, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood. 2001;98(1):85-92.
43. Freson K, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002;11(2):147-152.
44. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood. 2002;100(6):2040-2045.
45. Balduini CL, Pecci A, Loffredo G, et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost. 2004;91(1):129-140.
46. Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: The first trans-acting mutation causative for a human porphyria. Blood. 2007;109(6): 2618-2621.
47. Tubman VN, Levine JE, Campagna DR, et al. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood. 2007; 109(8):3297-3299.
48. Hollanda LM, Lima CS, Cunha AF, et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38(7): 807-812.
49. Calligaris R, Bottardi S, Cogoi S, Apezteguia I, Santoro C. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci USA. 1995;92(25):11598-11602.
50. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175.
51. Narla A, Ebert BL. Ribosomopathies: Human disorders of ribosome dysfunction. Blood. 2010; 115(16):3196-3205.
52. Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122(7):2439-2443.
53. Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med. 2014;20(7):748-753.
54. Parrella S, Aspesi A, Quarello P, et al. Loss of GATA-1 full length as a cause of Diamond- Blackfan anemia phenotype. Pediatr Blood Cancer. 2014;61(7):1319-1321.
55. Shimizu R, Takahashi S, Ohneda K, Engel JD, Yamamoto M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J. 2001;20(18): 5250-5260.
56. Weiss MJ, Mason PJ, Bessler M. What's in a name?. J Clin Invest. 2012;122(7):2346-2349.
57. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5(1):11-20.
58. Massey GV, Zipursky A, Chang MN, et al; Children's Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107(12): 4606-4613.
59. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group Study A2971. Blood. 2011;118(26): 6752-6759, quiz 6996.
60. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood. 2015; 126(8):943-949.
61. McElwaine S, Mulligan C, Groet J, et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol. 2004; 125(6):729-742.
62. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.
63. Maroz A, Stachorski L, Emmrich S, et al. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia. 2014;28(6):1259-1270.
64. Roberts I, Alford K, Hall G, et al; Oxford- Imperial Down Syndrome Cohort Study Group. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: Identification of a population at risk of leukemia. Blood. 2013;122(24):3908-3917.
65. Thiollier C, Lopez CK, Gerby B, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012;209(11):2017-2031.
66. Mercher T, Busson-Le Coniat M, Nguyen Khac F, et al. Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7. Genes Chromosomes Cancer. 2002;33(1):22-28.
67. Inaba H, Zhou Y, Abla O, et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: A retrospective international study. Blood. 2015;126(13):1575-1584.
68. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group experience. Blood. 2000;96(7):2405-2411.
69. Maloney KW, Taub JW, Ravindranath Y, Roberts I, Vyas P. Down syndrome preleukemia and leukemia. Pediatr Clin North Am. 2015; 62(1):121-137.
70. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst. 2005;97(3):226-231.
71. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stageselective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37(6):613-619.
72. Malinge S, Bliss-Moreau M, Kirsammer G, et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122(3):948-962.
73. Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45(11):1293-1299.
74. Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112(12):4507-4511.
75. Chou ST, Byrska-Bishop M, Tober JM, et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA. 2012;109(43):17573-17578.
76. Maclean GA, Menne TF, Guo G, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA. 2012; 109(43):17567-17572.
77. Byrska-Bishop M, VanDorn D, Campbell AE, et al. Pluripotent stem cells reveal erythroidspecific activities of the GATA1 N-terminus. J Clin Invest. 2015;125(3):993-1005.
78. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100(4):1123-1132.
79. Vannucchi AM, Pancrazzi A, Guglielmelli P, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167(3):849-858.
80. Zingariello M, Martelli F, Ciaffoni F, et al. Characterization of the TGF-b1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013;121(17):3345-3363.
81. Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ, Bresnick EH. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA. 2003; 100(15):8811-8816.
82. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994; 371(6494):221-226.
83. Rodrigues NP, Janzen V, Forkert R, et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood. 2005;106(2):477-484.
84. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10): 1012-1017.
85. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43(10):929-931.
86. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. 2011;118(10):2656-2658.
87. Pasquet M, Bellanné-Chantelot C, Tavitian S, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. 2013;121(5):822-829.
88. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015;125(1):56-70.
89. Nováková M, Žaliová M, Suková M, et al. Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. Haematologica. 2016;101(6):707-716.
90. Wlodarski MW, Hirabayashi S, Pastor V, et al; EWOG-MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387-1397.
91. West RR, Hsu AP, Holland SM, Cuellar- Rodriguez J, Hickstein DD. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica. 2014;99(2): 276-281.
92. Cohen JI, Dropulic L, Hsu AP, et al. Association of GATA2 deficiency with severe primary Epstein- Barr virus (EBV) infection and EBV-associated cancers. Clin Infect Dis. 2016;63(1):41-47.
93. Koegel AK, Hofmann I, Moffitt K, Degar B, Duncan C, Tubman VN. Acute lymphoblastic leukemia in a patient with MonoMAC syndrome/GATA2 haploinsufficiency. Pediatr Blood Cancer. 2016;63(10):1844-1847.
94. Zhang MY, Keel SB, Walsh T, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica. 2015;100(1):42-48.
95. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: A protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6): 809-821.
96. Dickinson RE, Milne P, Jardine L, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014;123(6):863-874.
97. Kazenwadel J, Secker GA, Liu YJ, et al. Loss-offunction germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood. 2012;119(5):1283-1291.
98. Hahn CN, Brautigan PJ, Chong CE, et al. Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia. Leukemia. 2015;29(8):1795-1797.
99. Gao J, Gentzler RD, Timms AE, et al. Heritable GATA2 mutations associated with familial AMLMDS: A case report and review of literature. J Hematol Oncol. 2014;7:36.
100. Webb G, Chen YY, Li KK, et al. Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease. J Hepatol. 2016;64(5):1190-1193.
101. Bigley V, Haniffa M, Doulatov S, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med. 2011;208(2):227-234.
102. Horwitz M, Sabath DE, Smithson WA, Radich J. A family inheriting different subtypes of acute myelogenous leukemia. Am J Hematol. 1996; 52(4):295-304.
103. Calvo KR, Hickstein DD, Holland SM. MonoMAC and GATA2 deficiency: Overlapping clinical and pathological features with aplastic anemia and idiopathic CD41 lymphocytopenia. Reply to Haematologica. 2012;97(4):058669. Haematologica. 2012;97(4):e12-e13.
104. Hirabayashi S, Strahm B, Urbaniak S, et al. Unexpected high frequency of GATA2 mutations in children with non-familial MDS and monosomy 7 [abstract]. Blood. 2012;120(21). Abstract 1699.
105. Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 2011;118(13): 3715-3720.
106. Grossman J, Cuellar-Rodriguez J, Gea- Banacloche J, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Biol Blood Marrow Transplant. 2014;20(12):1940-1948.
107. Churpek JE, Pyrtel K, Kanchi KL, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126(22):2484-2490.
108. Fujiwara T, Fukuhara N, Funayama R, et al. Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia. Ann Hematol. 2014;93(9):1515-1522.
109. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121(19):3830-3837, S1-S7.
110. Johnson KD, Hsu AP, Ryu MJ, et al. Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. J Clin Invest. 2012;122(10):3692-3704.
111. Liew CK, Simpson RJ, Kwan AH, et al. Zinc fingers as protein recognition motifs: Structural basis for the GATA-1/friend of GATA interaction. Proc Natl Acad Sci USA. 2005;102(3):583-588.
112. Wilkinson-White L, Lester KL, Ripin N, Jacques DA, Mitchell Guss J, Matthews JM. GATA1 directly mediates interactions with closely spaced pseudopalindromic but not distantly spaced double GATA sites on DNA. Protein Sci. 2015;24(10):1649-1659.